Replies to post #49738 on Biotech Values

[DewDiligence]

Here’s a SeekingAlpha write-up that’s almost as
bad as the one walldiver posted about IMCL:

http://biz.yahoo.com/seekingalpha/070716/40978_id.html?.v=1

>>
What is RNAi? In the past decade or so, RNA -- a cousin of DNA – has been shown to have a much more prominent role in cellular activity as a regulator of behavior. Modify RNA behavior and you can modify a disease. A couple of products are wending their way through the labs and development process. The closest one, for age related macular degeneration, is from what used to be called Sirna, now part of Merck (NYSE: MRK), the first RNAi deal to bite me you know where. Nothing else appears close [emphasis added].
<<

Actually, Sirna-027 (the RNAi drug for AMD from MRK) is not even in the lead! Bevasiranib from OPK is (#msg-21124315).

If anyone wants to write to SeekingAlpha to correct them, be my guest. I don’t do it because correcting mistakes at SeekingAlpha could become a full-time job :-)